MedTrace Logo

A Prospective Study of Spasticity in Individuals With Multiple Sclerosis

NCT01111435 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2012-03-05

No results posted yet for this study

Summary

This study is expected to contribute to the body of knowledge on the benefits of individuals with MS taking glatiramer acetate (Copaxone®). If patients have less spasticity when taking glatiramer acetate (Copaxone®), they may be more likely to have an improved quality of life.

The hypotheses for this study are:

1. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a decrease in spasticity.
2. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a change in perceptions of the impact of spasticity on their lives.

Conditions

  • Spasticity

Sponsors & Collaborators

  • Fraser, Cira, Ph.D., RN, ACNS-BC

    lead INDIV

Principal Investigators

  • Cira Fraser, PHD · Monmouth University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01111435 on ClinicalTrials.gov